CY 2024 Physician Fee Schedule Proposed Rule Summary – Part I
HFMA presents part I of three detailed summaries of the proposed rule relating to the Medicare physician fee schedule for CY 2024 and other revisions to Medicare Part B policies.
HFMA Comments on CY 2024 OPPS/ASC Proposed Rule
HFMA presents its comment letter to CMS on the CY 2024 OPPS/ASC Proposed Rule.
CY 2024 OPPS/ASC Proposed Rule Summary
HFMA presents a detailed summary of the proposed rule issued by CMS updating payments under the hospital outpatient prospective payment system and the ambulatory surgical center payment system for CY 2024.
FY 2024 IPPS/LTCH Final Rule Summary
HFMA presents a detailed summary of the final rule released by CMS describing federal FY 2024 policies and rates for Medicare’s inpatient prospective payment system and the long-term care hospital prospective payment system.
FY 2024 Skilled Nursing Facilities PPS Final Rule Summary
HFMA presents a detailed summary of the final rule updating the Medicare skilled nursing facility (SNF) payment rates for FY 2024.
FY 2024 Hospice Payment Rate Update Final Rule Summary
HFMA provides a detailed summary of the final rule updating the Medicare hospice payment rates, wage index, the cap amount and the quality reporting requirements for FY 2024.
FY 2024 Inpatient Psychiatric Facilities PPS Final Rule Summary
HFMA presents a detailed summary of the FY 2024 final rule released by CMS that rebases and revises the inpatient psychiatric facilities (IPF) PPS market basket to reflect a 2021 base year and makes other changes affecting IPF PPS rates.
FY 2024 Inpatient Rehabilitation Facility PPS Final Rule Summary
HFMA presents a detailed summary of the final rule issued by CMS on the Medicare inpatient rehabilitation facility prospective payment system for FY 2024.
Remedy for 340B-Acquired Drug Payment Policy Proposed Rule Summary
FMA presents a detailed summary of the proposed rule describing the Agency’s proposed actions to craft a remedy relating to the adjustment of Medicare payment rates for drugs acquired under the 340B Program from calendar 2018 through September 27, 2022.
Medicaid Drug Misclassification Proposed Rule Summary
The rule proposes to implement policies in the Medicaid Drug Rebate Program (MDRP) related to legislative requirements addressing drug misclassification, as well as drug pricing and product data misreporting by manufacturers.